{
    "clinical_study": {
        "@rank": "87366", 
        "arm_group": {
            "arm_group_label": "OCD patients", 
            "description": "OCD patients being treated with any dose of escitalopram"
        }, 
        "biospec_descr": {
            "textblock": "blood sample"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "To modeling the pharmacokinetic-pharmacodynamic(PK-PD) simulation with the plasma\n      concentration and the transporter occupancy from OCD patients treated with escitalopram.\n\n      To examine the effect of G2677T/A single nucleotide polymorphism(SNP) of ABCB1 gene to the\n      PK-PD modeling in OCD patients treated with escitalopram."
        }, 
        "brief_title": "Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "OCD", 
        "condition_browse": {
            "mesh_term": [
                "Obsessive-Compulsive Disorder", 
                "Compulsive Personality Disorder"
            ]
        }, 
        "detailed_description": {
            "textblock": "To measure plasma concentration of escitalopram in OCD patients treated with escitalopram.\n\n      To measure serotonin transporter occupancy by escitalopram in OCD patients treated with\n      escitalopram.\n\n      To genotype G2677T/A SNP of ABCB1 gene in OCD patients treated with escitalopram."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of OCD based on Diagnostic and Statistical Manual(DSM)-IV criteria\n\n          -  no change of escitalopram dosage in 6 weeks\n\n        Exclusion Criteria:\n\n          -  psychiatric comorbidity other than OCD\n\n          -  History of head injury, epilepsy, other general medical disorder"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "35 Years", 
            "minimum_age": "20 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "OCD patients"
            }
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01936051", 
            "org_study_id": "H-1109-086-378", 
            "secondary_id": "2011-0931"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexetimide", 
                "Citalopram", 
                "Serotonin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 2, 2013", 
        "location": {
            "contact": {
                "email": "parkjinu78@naver.com", 
                "last_name": "Jin Woo Park, MD", 
                "phone": "82-2-3668-7666"
            }, 
            "contact_backup": {
                "last_name": "Jun Soo Kwon, MD, PhD", 
                "phone": "82-2-2072-2450"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Jun Soo Kwon, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Euitae Kim, MD, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients", 
        "overall_contact": {
            "email": "parkjinu78@naver.com", 
            "last_name": "Jin Woo Park, M.D.", 
            "phone": "82-19-426-4506"
        }, 
        "overall_contact_backup": {
            "email": "euitae.kim@gmail.com", 
            "last_name": "Euitae Kim, M.D., Ph.D.", 
            "phone": "82-10-9419-1058"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Jun Soo Kwon, M.D, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry for Health, Welfare and Family Affairs", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "serotonin transporter occupancy", 
            "safety_issue": "No", 
            "time_frame": "72hr after oral administration of escitalopram"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01936051"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul National University Hospital", 
            "investigator_full_name": "Jun Soo Kwon", 
            "investigator_title": "Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in OCD Patients", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "genotype", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "scale for the severity of Obsessive-compulsive symptoms", 
                "measure": "Yale-Brown Obsessive Compulsive Scale(Y-BOCS) Score", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "serotonin transporter occupancy measured at 5 hour and 24 hour after oral dose of escitalopram", 
                "measure": "serotonin transporter occupancy", 
                "safety_issue": "No", 
                "time_frame": "within the first 24hrs after oral administration of escitalopram"
            }, 
            {
                "description": "plasma concentration of escitalopram at baseline, 1, 2, 3, 5, 8, 10, 24, 48, 72 hour after oral dose of escitalopram", 
                "measure": "escitalopram plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "within 72 hours after oral administration of escitalopram"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}